The anti-anginal agent ranolazine, in phase 3 clinical trials, reduced anginal frequency in patients experiencing 3 or more anginal attacks per week despite daily treatment with amlodipine 10 mg/d said Peter Stone, MD, lead investigator of the Evaluation of Ranolazine in Chronic Angina (ERICA) trial.
The anti-anginal agent ranolazine, in phase 3 clinical trials, reduced anginal frequency in patients experiencing 3 or more anginal attacks per week despite daily treatment with amlodipine 10 mg/d said Peter Stone, MD, lead investigator of the Evaluation of Ranolazine in Chronic Angina (ERICA) trial.
"Ranolazine has a novel pharmacodynamic profile with anti-ischemic properties that do not depend on changes in determinants of myocardial oxygen demand of heart rate, blood pressure, and contractility; therefore, it provides complementary therapy to existing agents that depend on hemodynamics," said Dr Stone, co-director of the Samuel A. Levine Cardiac Unit at Brigham and Women's Hospital in Boston, Mass. "It improves the manifestations of ischemia, such as myocardial stiffness and increased wall tension."
Ranolazine acts by inhibiting the late inward sodium current and thereby inhibits all of the subsequent consequences of myocardial ischemia, Dr Stone said.
Similarly, ranolazine has been shown to be effective in combination with other anti-anginal agents in routine doses in reducing angina frequency and time to 1 mm of ST depression and in increasing exercise time, Dr Stone said.
In ERICA, 565 patients with a documented diagnosis of coronary artery disease and at least 3 angina attacks weekly who were already taking the maximum labeled dose of amlodipine (10 mg/d) for at least 2 weeks were randomized to ranolazine 500 mg twice daily titrated up to 1,000 mg twice daily, or placebo. Long-acting nitrates were permitted and used by 45% of patients enrolled.
At baseline, patients had nearly 6 angina attacks per week and required almost 5 nitroglycerin tablets per week.
Compared with placebo, ranolazine significantly decreased the mean number of angina episodes per week (P=.028), improved the angina frequency domain of the Seattle Angina Questionnaire (P=.008), and reduced mean weekly nitroglycerin consumption (P=.014) during the 6-week assessment period.
The treatment effect of ranolazine was consistent across the subgroups analyzed: users versus non-users of long-acting nitrates, men versus women, and patients aged <65 versus ≥65 years.
The anti-anginal effects of ranolazine occurred without significant effects on blood pressure and heart rate, Dr Stone said.
Adverse events were more common in the ranolazine versus the placebo group (21% vs 6%), but serious adverse events occurred in only 1% of each group, and only 1% of patients in each group withdrew from the study due to adverse events.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More